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The present study aimed at characterizing the epitopes recognized by coxsackievirus B4 (CBV4)-specific T-cell lines established from 23
children with type 1 diabetes (T1D) and 29 healthy children with T1D risk-associated HLA genotypes. Responsiveness to VP1 region was
dependent on the specific infection history as 55% of the T-cell lines from donors with neutralizing antibodies to CBV serotypes responded to
VP1 peptides compared to none of the T-cell lines from other donors (P = 0.01). The pattern of recognized peptides was dependent of the
HLA genotype. Forty-two percent of the T-cell lines from donors carrying the HLA-(DR4)-DQB1*0302 haplotype responded to VP1
peptides 71–80 compared to none of the T-cell lines from donors without this haplotype (P = 0.02). No evidence for the existence of
diabetes-specific epitopes was found. Only few epitopes were exclusive recognized by T cells from diabetic children, and in each case only
one or two T-cell lines were responding.
D 2003 Elsevier Inc. All rights reserved.Keywords: Coxsackievirus B4 (CBV4); Enterovirus; T-cell epitope; Cell-mediated immunity; HLA; Type 1 diabetes (T1D)Introduction
Enteroviruses are small, nonenveloped viruses with sin-
gle-stranded RNA genome of positive polarity. The capsids
of enteroviruses are composed of four structural proteins:
VP1, VP2 and VP3 are on the virus surface and VP4 is
internal. In addition, seven nonstructural proteins 2A, 2B,
2C, 3A, 3 B, 3C and 3D are produced during viral
replication in infected cells (Racaniello, 2001). When the
genomes of the enteroviruses are compared, nonstructural
proteins and the VP4 structural protein are the most con-
served between the serotypes while the most variable
protein is VP1 (Po¨yry et al., 1996).
Enteroviruses are common human pathogens, but most
enterovirus infections are asymptomatic or accompanied by0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: jane.marttila@utu.fi (J. Marttila).only mild common cold type symptoms. In some cases,
enterovirus infections can lead to serious illness, especially
in infants and the immunocompromised subjects (Pallansch
and Roos, 2001). Paralytic polio is the classic example, but
the specific clinical manifestations also include rash, hand
foot and mouth disease, herpangina and pleurodynia. The
clinical pictures are partly associated with specific entero-
virus serotypes but in many cases, certain type of disease
can be caused by several different serotypes.
Serotype specific neutralizing antibodies are important in
the protection against enterovirus infections. The major
neutralizing antigenic sites are located on the VP1 protein
and to lesser extent on VP2 and VP3 proteins (Hogle et al.,
1985; Mateu, 1995; Minor et al., 1986). T cells provide help
for the B cells to produce antibodies but the overall
significance of enterovirus-specific T-cell immunity is not
fully understood (Pallansch and Roos, 2001). Anti-viral
immune response may be involved in the development of
disease-associated complications like meningitis, myocardi-
tis and generalized serious infection in newborns (Beck and
Table 1
Characteristics of the study subjects
DM Age
(years)
HLA-DR
(deduced)
HLA-DQA1* HLA-DQB1* Generated
T-cell line
CBV-ab
no 4 3, x 05 02, x  +
no 4 3, x 05 02, x  
no 8 3, 3 05 02, 02 + +
no 12 3, 9 05 02, 0303 + +
no 13 1, 3 05 02, 0501 + +
no 6 4, 7 0201 02, 0302  
no 9 4, x 0302, x  +
no 10 4, 6 0302, 0604  +
no 6 4, 7 0201 02, 0302  
no 12 4, 8 0302, 04 + +
no 16 4, 4 0302 + +
no 13 4, 4 0302 + +
no 16 4, 4 0302 + +
no 10 4, 9 03 0302, 0303 + +
no 14 1, 4 0302, 0501 + +
no 8 1, 4 0302, 0501 + +
no 14 1, 4 0302, 0501 + +
no 6 3, 4 05 02, 0302  +
no 8 3, 4 05 02, 0302 + +
no 10 3, 4 05 02, 0302 + 
no 4 3, 4 05 02, 0302 + +
no 6 3, 4 05 02, 0302 + 
no 4 3, 4 05 02, 0302 + +
no 6 3, 4 05 02, 0302 + 
no 7 3, 4 05 02, 0302 + +
no 9 7, 8 0201 02, 04 + +
no 7 7, 9 03, 0201 02, 0303 + 
no 4 2, 3 05 02, 0502 + +
no 14 2, 9 03 0303, 0602 + +
yes 10 3, x 05 02, x  
J. Marttila et al. / Virology 319 (2004) 27–3528Tracy, 1990; Henke et al., 1995). T cells may also mediate
the possible effect of enterovirus infections in the patho-
genesis of type 1 diabetes. Especially coxsackie B viruses
(CBV) have been indicated as environmental triggers initi-
ating autoimmune destruction of insulin-producing pancre-
atic h-cells (Andreoletti et al., 1997; Banatvala et al., 1985;
Frisk et al., 1985; Hiltunen et al., 1997; Hyo¨ty, 2002; Hyo¨ty
et al., 1995; Jones and Crosby, 1996; Juhela et al., 1999;
Nairn et al., 1999).
In our previous study, we demonstrated that epitopes in
CBV4 structural proteins, recognized by T cells derived
from adult subjects, concentrate in the VP4 and VP2
proteins, while only few epitopes could be found in the
VP3 and VP1 proteins. As the amino acid sequence of the
VP4 and VP2 proteins is more conserved among different
enterovirus serotypes than that of VP1 and VP3, the results
suggest that T-cell cross-reactivity between enteroviruses
contributed to these recognition patterns. T-cell cross-reac-
tivity was also supported by the similarity of the recognized
peptides regardless of the presence of CBV4-specific neu-
tralizing antibodies of the T-cell donors (Marttila et al.,
2002).
The present study aimed to further characterize the
epitopes recognized by CBV4-specific T cells and the effect
of infection history and HLA genotype on the recognition
pattern. The possibility of diabetes-related pattern was also
studied using blood samples from 23 children with type 1
diabetes (T1D) and from 29 healthy children with T1D risk-
associated HLA genotypes.
yes 9 3, 9 05 02, 0303  +
yes 16 1, 3 05 02, 0501 + 
yes 14 1, 3 05 02, 0501 + 
yes 13 3, 6 05 02, 0603 + +
yes 4 3, 6 05 02, 0604 + 
yes 10 4, x 0302, x  +
yes 7 4, 6 0302, 0604  +
yes 14 4, 7 0201 02, 0302 + +
yes 15 4, 8 0302, 04 + +
yes 9 4, 8 0302, 04 + +
yes 12 4, 8 0302, 04 + +
yes 12 1, 4 0302, 0501 + +
yes 11 4, 6 0302, 0603 + +
yes 8 4, 6 0302, 0604 + 
yes 6 3, 4 05 02, 0302  
yes 4 3, 4 05 02, 0302  
yes 14 3, 4 05 02, 0302 + +
yes 11 3, 4 05 02, 0302 + +
yes 11 3, 4 05 02, 0302 + +
yes 9 7, x 0201 02, x  
yes 13 7, 8 0201 02, 04 + +
yes 12 5, 7 05, 0201 02, 0301 + +Results
Effect of the donor characteristics to the establishment of
CBV4-specific T-cell lines
Twenty-three children with type 1 diabetes (T1D) and
29 children with T1D risk-associated HLA genotypes
donated blood for the study (Table 1). An attempt to
generate a CBV4-specific T-cell line was made with
lymphocytes from each donor using repeated stimulations
with the CBV4 lysate antigen. After one or more repeated
CBV4 stimulation, 73% of the T-cell lines (38 out of 52)
recognized CBV4 antigen and at least one CBV4 peptide
pool and the remaining 27% (14 out of 52) failed to
respond to CBV4 antigen or CBV4 peptides (Table 1).
CBV4-specific T-cell lines could be established from 70%
of the donors with type 1 diabetes and from 76% of the
control children (P = 0.755, Fisher’s Exact test) (Table 1).
The children whose cells allowed the generation of CBV4-
specific T-cell lines were older than children whose cells
did not allow the generation of CBV4-specific T-cell lines
(median age 12, range 4–16 years vs. median 7, range 4–
10 years, P = 0.0021, Mann Whitney U test), and they also
showed a tendency to be more often positive for neutral-
izing antibodies to at least one of the CBV serotypes (79%vs. 50%; P = 0.081, Fisher’s Exact test) (Table 1). Donors
of both the groups had similar frequency of neutralizing
antibodies to echo 6, 9, 11 and 30 viruses (P z 0.999,
Fisher’s Exact test) and there were no differences in the
distribution of the four analyzed HLA genotypes (P =
0.755, Chi Square test).
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CBV4-specific T-cell lines were established from 38 of
the 52 donors. The responses to 119 synthetic peptides
covering the sequences of CBV4 structural proteins VP4,
VP2, VP3 and VP1, and the nonstructural 2C protein, were
analyzed. In the first phase, the epitopes were mapped by
using 23 pools of five to six CBV4 peptides (Fig. 1) and in
the next phase, the responses to single peptides from
responding pools were studied (Figs. 2 and 3 and Table 2).
Single peptides responsible for the pool responses could be
identified for 33 of 38 CBV4-specific T-cell lines. VP2
peptides 26–29 (including amino acids (aa) LTIYPHQ-
WINLRTNNSATIVMPYINSVPMDNMFRHNNFTLM-
IIPFAPLDY) evoked responses most often; 61% of the
CBV4-specific T-cell lines recognized one of these peptides
and 33% recognized more than two of these four peptides
(Figs. 2 and 3). VP4 peptides 3 (aa GNSIIHYTNINYYK-
DAASNS) and/or 4 (aa NYYKDAASNSANRQDFTQDT)
were also commonly recognized as 39% of the CBV4-
specific T-cell lines recognized these peptide(s) (Figs. 2
and 3). The 2C peptide 22 (aa ILFTSPFVLASTNAGSI-
NAP) evoked responses with 30% of the T-cell lines (Figs. 2
and 3). Relative frequency of recognized peptides in various
polyproteins was calculated with the formula [(number of
recognized peptides)/(number of T-cell lines  total number
of peptides)]  100%. On average, 15% of VP4 peptides,
10% of the VP2 peptides, 4% of the VP3 peptides, 4% of the
VP1 peptides and 6% of the 2C peptides were recognized
(Table 2).
Epitope specificity of CBV4-specific T-cell lines: correlation
with neutralizing antibodies against CBV serotypes
Neutralizing antibodies to all coxsackie B virus serotypes
(CBV1, CBV2, CBV3, CBV4, CBV5, CBV6) as well as to
some common echoviruses (EV6, EV9, EV11) and CAV9
were tested from sera of 52 donors. Thirteen percent of the
children were seronegative to all tested enterovirus serotypes,
one donor had antibodies to nine examined serotypes, but on
the average, the children were seropositive for three sero-
types. The age of the children correlated directly to the
frequency of the neutralizing antibodies to tested serotypes
(P = 0.007, Spearman Rank Correlation). Seventy-one per-
cent of children had neutralizing antibodies to at least one of
the CBV serotypes (Table 1). No significant difference
between children with T1D and control children was detected
in the enterovirus seropositivity. None of the eight T-cell lines
established from donors without neutralizing antibodies to
CBV serotypes responded to VP1 peptide pool(s), whereas
55% of the T-cell lines established from donors with neutral-
izing antibodies against at least one of the CBV serotypes
responded to this region (P = 0.006, Fisher’s Exact test). The
recognition of VP1 peptide pool(s) did not differ between T-
cell lines established from donors with or without neutraliz-
ing antibodies to echovirus 6, 9, 11 and/or 30 serotypes (P >0.999 Fisher’s Exact test). No significant difference between
the recognition of VP3 peptide pool(s) was detected when T-
cell lines established from donors with or without neutraliz-
ing antibodies to CBV serotypes were compared (P = 0.232
Fisher’s Exact test) but positive [stimulation index (SI) z 2]
responses to VP3 peptide pools had a tendency to be higher
with T-cell lines established from donors with neutralizing
antibodies to CBV (median SI = 3.6, range 2.0–17.3) than
with T-cell lines from donors without neutralizing antibodies
to CBV (median SI = 2.2, range 2.0–3.2) (P = 0.067 Mann–
Whitney U test) (Fig. 1). When relative frequency of recog-
nized peptides was calculated, T-cell lines established from
donors with neutralizing antibodies to CB viruses responded
to higher proportion of peptides in VP3 and VP1 compared to
T-cell lines from donors without neutralizing antibodies to
CBVs (P = 0.016 and P = 0.002, Fisher’s Exact test) (Table
2). In contrast, VP2 and 2C peptides were less frequently
recognized in CBV antibody positive than negative donors
(P = 0.001 and P = 0.001, Fisher’s Exact test) (Table 2).
Specificity of CBV4-specific T-cell lines: effect of HLA
genotype of the donors
T-cell lines established from each donor recognized up to
20 (out of 119) different peptides from CBV4 VP4, VP2,
VP3, VP1 and 2C proteins with a median of six recognized
peptides. Despite individual patterns of peptide recognition,
similarities could be detected between the donors with similar
HLA genotypes. Ten out of the 24 (42%) CBV4-specific T-
cell lines established from donors carrying HLA-(DR4)-
DQB1*0302 haplotype recognized VP1 peptide pool 71–
75 and/or 76–80 and further at least one of the single peptides
within the region, whereas none of the 12 T-cell lines
established from donors without HLA-(DR4)-DQB1*0302
had a positive response to this region (P = 0.015, Fisher’s
Exact test) (Fig. 2). Eleven (52%) of these T-cell lines
responded to both of the VP4 peptides 3 and 4, whereas none
of the 12 lines from donors without this haplotype responded
to both of these peptides (P= 0.002, Fisher’s Exact test) (Fig.
2). Also T-cell responses to 2C peptides 17 (aa
PDHFDGYKQQAVV IMDDLCQ ) a n d 1 8 ( a a
AVVIMDDLCQNPDGKDVSLF) showed a tendency to be
associated with HLA-(DR4)-DQB1*0302 haplotype. All six
CBV4-specific T-cell lines responding to these peptides were
established from HLA-(DR4)-DQB1*0302 positive donors
(Fig. 2). The specific association was also demonstrated by
the fact that two out of three T-cell lines established from
homozygote donors with HLA-(DR4)-DQB1*0302
responded to each of the regions, VP1 71–80 and 2C 17–
18 and VP4 3–4, whereas one of them had positive response
only to VP4 peptide 3 (response to VP4 peptide 4 was
borderline, SI = 1.9). One T-cell line established from
homozygote donor carrying HLA-(DR3)-DQA1*05-
DQB1*02 recognized VP2 pept ides 13 – 14 (aa
QPTQPDVATCRFYTLNSVKWEMGSAGWW-WK), VP1
peptide 68 (aa LRRKMEMFTYIRCDMELTFV) and 2C
Fig. 1. Responses of coxsackievirus B4 (CBV4)-specific T-cell lines established from donors with (left panel) or without (right panel) neutralizing antibodies to
CB viruses to 23 CBV4 peptide pools from the VP0 (VP4 + VP2), VP3, VP1, 2C protein regions. The responses are expressed as stimulation indices (SI).
Median value in each group is shown as the horizontal line in the box. The outlines of the boxes show values between 25th and 75th percentiles while the open
circles are values outside this range.
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Fig. 2. Responses of coxsackievirus B4 (CBV4)-specific T-cell lines established from donors with different HLA genotypes to CBV4 peptides: VP4 peptides
1–6, VP2 peptides 7–32, VP3 peptides 33–56, VP4 peptides 57–86 and 2C peptides 1–33. Boxes represent areas including different peptides (peptides 3–4,
7–10, 13–16, 26–29, 68–69, 73–79 and 2C peptides 1–12, 17–18).
J. Marttila et al. / Virology 319 (2004) 27–35 31peptide 9 (aa QYFAHYCRKYAPLYAAEARK). These epi-
topes were included in the regions VP2 13–16, VP1 68–69
and 2C 1–12which were more commonly recognized with T-Fig. 3. Number of T-cell lines responding to each CBV4 VP4 peptides 1–6, VP2
1–33. White bars, children with type 1 diabetes; gray bars, control children.cell lines established from donors carrying HLA-(DR3)-
DQA1*05-DQB1*02 when compared to donors with
HLA-(DR3/4)-DQA1*05-DQB1*02/0302 or those withoutpeptides 7–32, VP3 peptides 33–56, VP1 peptides 57–86 and 2C peptides
Table 2
Relative frequency of recognized VP4, VP2, VP3, VP1 and 2C peptides by CBV4-specific T-cell lines in various comparison groups
T-cell line donors CBV4 peptides (number of the peptides in each protein)
VP4 peptides
(n = 6)
VP2 peptides
(n = 26)
VP3 peptides
(n = 24)
VP1 peptides
(n = 29)
2C peptides
(n = 33)
All donors n = 33 15 10 4 4 6
CBV-ab + n = 28 17 8 P = 0.001 4 P = 0.016 5 P = 0.002 4 P = 0.001
CBV-ab n = 5 7 18 0 0 12
HLA-(DR4)-DQB1*0302/x n = 21 21 P = 0.003 7 P = 0.015 4 5 5 P = 0.078
HLA-(DR3)-
DQA1*0201-
DQB1*05/y
n = 7 2 13 1 2 9
Controls n = 16 18 10 2 P = 0.052 6 P = 0.011 6
Diabetic children n = 15 12 10 5 2 6
x = another HLA haplotype than HLA-(DR2)-DQB1*0602, y = another HLA haplotype than HLA-(DR4)-DQB1*0302 or HLA-(DR2)-DQB1*0602.
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VP2 7–10 was commonly recognized with those T-cell
lines (Fig. 2). In general, relative frequency of recognized
single VP4 peptides was higher (P = 0.003, Fisher’s
Exact test) and VP2 peptides lower (P = 0.015, Fisher’s
Exact test) when T-cell lines established from donors with
HLA-(DR4)-DQB1*0302 haplotype were compared to T-
cell lines from donors with HLA-(DR3)-DQA1*05-
DQB1*02 and without HLA-(DR4)-DQB1*0302 haplotype
(Table 2). It was also found that T-cell lines established from
donors with HLA-(DR1)-DQB1*0501 responded to large
number of the peptides (median 11), mainly in region of the
VP2 (relative frequency of recognized VP2 peptides was
21%, P < 0.0001 when compared to all T-cell lines, Fisher’s
Exact test) and 2C (relative frequency of recognized 2C
peptides was 13%, P < 0.0001, Fisher’s Exact test) proteins
(Table 2).
Responses with CBV4-specific T-cell lines: comparison
between diabetic and control children
None of the peptides was recognized by the majority of T-
cell lines established from diabetic but not control subjects
although, some single peptides were recognized solely by T
cells from diabetic donors. VP2 peptides 15, 16, 23, 30, VP3
peptides 37, 47, 48, 51, 52, 53, 55, VP1 peptide 63 and 2C
peptides 1, 5, 7, 8, 11, 12, 16, 25, 32, 33 were this kind of
peptides. However, only 1 or 2 of the 15 lines from diabetic
children recognized them. Similarly, none of the peptide was
preferentially recognized by control but not diabetic children
derived lines although few single peptides were recognized
solely by Tcells from healthy controls including VP4 peptide
5 VP2 peptides 7, 20, VP3 peptide 41, VP1 peptides 67, 69,
76, 78, 83, 84 and 2C peptides 19, 23, 24, 26, 29, 30, 31 (Fig.
3). Relative frequency of recognized VP1 peptides was lower
(P = 0.011, Fisher’s Exact test) and relative frequency of
recognized VP3 peptides was higher (P = 0.052, Fisher’s
Exact test) when T-cell lines established from diabetic donors
were compared to T-cell lines from healthy control subjects
(Table 2).Discussion
In the present study, we analyzed the T-cell responses
against CBV4 peptides by CBV4-specific T-cell lines estab-
lished from 23 children with T1D and from 29 healthy
children with T1D risk-associated HLA genotypes. As
expected, the generation of the CBV4-specifc T-cell lines
was significantly more successful if the donors had neutral-
izing antibodies against at least one of the CBV serotypes.
Also the age of the donors was critical, lines were established
more often in older donors, indicating probably a stronger
proliferation response to enteroviruses induced by a higher
number of past enterovirus infections.
These new results were in good agreement with our
previous studies (Marttila et al., 2001, 2002). This is also
the case for the recognition of 2C peptide 4 (WLKVKIL-
PEVKEKHEFLSRL) which includes the homology se-
quence (PEVKEK) with human GAD65 protein.
Responses were found in donors with HLA-(DR1)-
DQB1*0501 haplotype and the peptide was recognized
as frequently by T cells from donors with T1D (two out
of three) and healthy control subjects (one out of three).
VP2 peptides 26–29, VP4 peptides 3–4 and 2C peptide
22, which were most often recognized in the present
study, were also common epitopes in our previous
studies. They were recognized by T cells from donors
with several different HLA genotypes. In general, the
donors with similar HLA genotypes recognize the same
pattern of peptides because HLA molecules define which
type of peptides are presented to T cells (Rammensee et
al., 1995). The common peptides probably contain many
overlapping epitopes recognized by T cells from donors
with different HLA genotypes, whereas less commonly
recognized peptides may contain only one epitope recog-
nized by T cells from donors with a shared HLA
molecule.
In the present study, we found three regions in which
the recognition was associated with the carriage of HLA-
(DR4)-DQB1*0302 haplotype by the donors. Because of
the strong linkage between DR and DQ molecule, we do
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ed by DR or DQ molecules. VP4 peptides 3–4 (epitope
probably located in the overlapping region because both
of the peptides were recognized), VP1 peptides 71–80
and 2C peptides 17–18 were recognized only with T-cell
lines established from donors with HLA-(DR4)-
DQB1*0302 haplotype. Our earlier study with healthy
adult donors demonstrated that in addition to the
responses restricted by HLA-(DR4)-DQB1*0302
haplotype, both VP4 peptides 3 and 4 evoked responses
also with T cells established from donors with HLA-DR1
or -DR2 molecule, VP1 peptide 75 also with T cells from
donors with HLA-DR1,6 and HLA-DR2,3 genotypes and
2C peptides 17, 18 also with T cells from donors with
HLA-DR3 molecule, whereas VP1 peptides 73, 74, 76,
78, 79, 80 evoked responses only with T cells established
from donors with HLA-DR4 (Marttila et al., 2001, 2002).
Varela-Calvino et al. (2002) studied T-cell responses to
CBV4 by measuring proliferation and cytokine production
of peripheral blood mononuclear cells (PBMC) in response
to the Escherichia coli-produced fusion proteins combined
with various CBV4 polypeptides (VP4, VP2, VP3 and
VP1 and 2C). They found proliferation responses most
often to VP2 protein (in 28% of the donors) which is
consistent with our findings (in 67% of the CBV4-specific
T-cell lines). However, they found only few responses to
2C and VP4 regions, which were important targets of the
T-cell immunity in our studies (61% and 42% of the
CBV4-specific T-cell lines, respectively). In addition, their
results suggested that the quality of the immune response
to CBV4 antigens differed significantly between patients
with T1D (newly and/or long term) and control subjects.
Proliferation responses against VP2 protein were signifi-
cantly reduced and IFN-g production against VP2, VP3
and 2C proteins increased in patients with T1D (mainly
newly diagnosed) in comparison with control subjects. In
the present study, a tendency to more recognition of
peptides in VP3 and less in VP1 by T-cell lines established
from diabetic children was found. No difference in the
recognition of other polypeptides was detected. Our meth-
odology may be more accurate in defining recognition of
epitopes recognized by CD4 positive T cells while it is not
able to reveal all regulatory influences seen in the sum-
mation response of peripheral blood cells. On the other
hand, the establishment of T-cell line as such is influenced
by several factors. Differences in the matching of the
diabetes and control groups might also be important. If
responses specific to diabetes and not just specific for
diabetes-associated HLA alleles are sought, the diabetic
and control children should be very tightly matched for
HLA genotypes. Varela-Calvino et al. did not present
information of the HLA-DRX molecule associated with
T1D risk allele (HLA-DR4,X), which could also be
important. For example, in this work, T cells from donor
with HLA-(DR1)-DQB1*501 either with HLA-(DR3)-
DQA1*05 or HLA-(DR4)-DQB1*0302 recognized largenumber of the peptides mainly in the region of the VP2
and 2C proteins.
The mechanism of HLA-related susceptibility to the
disease may be associated with the selection of recog-
nized epitopes but other factors must also be important
because only a minority of children with a HLA risk
genotype ever develop the disease. A new finding in our
present work is that only CBV4-specific T-cell lines
established from children with neutralizing antibodies
against at least one of the CBV serotypes responded to
VP1 and VP3 peptides. This suggests that the T-cell
response to VP1 region is cross-reactive between CB
viruses but not between CB viruses and other enter-
oviruses which is consistent with the fact that VP1
protein is the most variable region between different
enteroviruses. T-cell response to VP3 protein seems also
to be cross-reactive between CB viruses because no
responses to single VP3 peptide were detected with T
cells from donors without neutralizing antibodies to at
least one of CBV serotypes. The CBV4-specific T-cell
responses to VP1 and VP3 peptides show that the pattern
of the recognized peptides may vary depending on the
infection history of the children. Thus, due to different
enterovirus infection history, children with identical HLA
genotypes might be able to recognize different T-cell
epitopes. One child might recognize a mimicry peptide
in both enterovirus and self-antigen while another without
a history of a particular enterovirus infection would lack
the responsiveness to a mimicry peptide. Recognition of a
mimicry peptide could activate the autoreactive T cells
and lead to one step closer to T1D. Certainly, also other
factors than HLA type and infection history may play a
role. For example, immunoregulatory CD4+CD25++ T
cells or NKT cells, which control T-cell activation, may
be able to inhibit the activation of autoreactive T cells
and development of T1D (Baecher-Allan et al., 2001;
Hammond and Godfrey, 2002; Kukreja et al., 2002; van
der Vliet et al., 2001; Wing et al., 2002).
In conclusion, T-cell lines from children with T1D risk-
associated HLA genotypes recognize different epitopes than
T-cell lines from other children and the patterns also vary
between different HLA-risk genotypes. However, the chil-
dren with T1D seem to respond to the same epitopes as HLA-
matched control subjects. The past exposure to enteroviruses
had an effect on the frequency of T-cell epitope recognition.
Whether these differences have any relevance for the patho-
genesis of the disease remains to be clarified.Materials and Methods
Subjects
A total of 52 children was studied including 23 type 1
diabetic (T1D) patients aged 4–16 years (median 11 years),
and 29 healthy control children with T1D risk-associated
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haplotypes associated with the risk for or protection against
T1D were analyzed from all 52 donors using a screening
system described earlier (Sjo¨roos et al., 1995; Nejetsev et
al., 1999). Nine children with T1D and 12 control children
were positive for HLA-(DR4)-DQB1*0302, 6 children with
T1D and 5 control children had HLA-(DR3)-DQA1*05-
DQB1*02. Five children with T1D and 8 control children
were positive for both of these T1D risk associated hap-
lotypes and 3 children with T1D and 4 control children had
neither of these risk haplotypes (Table 1). In the case of 38
donors whose blood allowed the establishment of CBV4-
specific T-cell lines, preliminary typing was completed by a
low-resolution full-house typing detecting all major DR-DQ
haplotypes in Northern European population (Laaksonen et
al., 2002) (Table 1). The Joint Ethics Committee of the
Turku University and Turku University Hospital approved
this study and informed consent was obtained from all
parents/guardians.
T-cell lines
Peripheral blood mononuclear cells (PBMC) were iso-
lated from heparinized venous blood by Ficoll-Paque
(Uppsala, Sweden) gradient centrifugation. PBMC (2 
106/ml) were incubated with the CBV4 antigen (10 Ag/ml)
in RPMI 1640 medium supplemented with 10% human
AB serum, gentamycin sulphate (10 Ag/ml), HEPES buffer
solution 1 M (20 Al/ml) and 3% glutamine (10 Al/ml).
After 7 days, fresh medium supplemented with 0.5 ng/ml
recombinant human IL-2 (R&D Systems Inc., Minneapolis,
MN, USA) was added every second or third day. After a
total of 14 days from the beginning, the T cells were
restimulated with both CBV4 antigen and irradiated (30
Gy) autologous antigen-presenting cells (2  106 PBMC/
ml). T-cell lines were restimulated at 7-day intervals, IL-2
was added 2 days after antigen stimulation and at 2- to 3-
day intervals thereafter. All T-cell lines had more than two
cycles of stimulation with CBV4 virus antigen, irradiated
autologous APC and IL-2. The T-cell lines did not respond
to control cell lysate. An average of 96% of cells were
CD3 positive, 42% CD4 positive and 30% CD8 positive
when the phenotype of 25 CBV4-specific T-cell lines were
analyzed with flow cytometry (Facscan, Becton Dickinson,
Mountain View, CA, USA) using FITC- or Phycoerythrin-
conjugated mAb (Coulter, Hialeah, FL, USA) for cell
surface markers.
CBV4 antigens
Coxsackievirus B4 (J.V.B.) was grown in ML-2 LLC
cells (ATCC). Infected cell cultures were harvested when
cells detached freely from the flask surface. The infected
cells and supernatant fluids were frozen and quickly
thawed three times. This lysate was inactivated with h-
propiolactone and used as CBV4 lysate antigen. Thepreparation of purified coxsackie B4 antigen was done
by sucrose gradient centrifugation. Protein concentrations
were measured using the Pierce BCA protein assay reagent
(Pierce, Rockford, USA). CBV4 lysate antigen was used at
a final concentration of 10 Ag/ml and purified CBV4
antigen at 1 Ag/ml.
Peptides
One hundred and nineteen 20-amino acid (aa)-long
synthetic peptides with 10 aa overlaps covering the whole
CBV4 structural proteins (Marttila et al., 2002) and 2C
protein (Marttila et al., 2001) sequences of the JBV strain
(Jenkins et al., 1987) were synthesized by F-moc [N-(9-
fluorenyl)methoxycarbonyl] chemistry on a simultaneous
multiple peptide synthesizer (SMPS 350, Zinsser Analytic,
Frankfurt a/M, Germany). Purity of the peptides was ana-
lyzed by reversed-phase HPLC (Hewlett Packard 1100
series, Waldbronn, Germany). In the first phase, the epitope
was mapped by using 23 pools. Pools of five VP0 peptides
were VP1–5, VP6–10, VP11–15, VP16–20, VP21–25,
VP26–30. Pools of five VP3 peptides were VP31–35,
VP36–40, VP41–45, VP46–50, VP51–55. Pools of five
to six VP1 peptides were VP56–60, VP61–65, VP66–70,
VP71–75, VP76–80, VP81–86. Pools of five to six 2C
peptides were 2C1–6, 2C7–12, 2C13–18, 2C19–23,
2C24–28, 2C29–33.
Lymphocyte proliferation assay
Triplicate cultures of 5–10  103 T cells per well were
incubated with 2  104 antigen presenting cells (PBMC)
and antigen in 200 Al volumes in 96-well round-bottomed
microtiter plates for 2 days. Tritiated thymidine (2 ACi/ml)
was added 18 h before harvesting the cultures. Incorporated
radioactivity was measured by 1450 Microbeta Plus liquid
scintillation counter (Wallac, Turku, Finland). Stimulation
index (SI) was calculated by dividing the median of stim-
ulated triplicate culture wells by the median of the unstimu-
lated wells.
Neutralizing antibodies
Serotype specific antibodies against coxsackievirus B
(CBV) serotypes 1–6, echovirus (EV) serotypes 6, 9 and
11 and coxsackievirus A (CAV) serotype 9 were analyzed
using standard plaque neutralization assay. Titers below 4
were considered negative.
Statistical analysis
The statistical significance of the differences in T-cell
responses to the CBV4 peptides between different groups
was analyzed using Fisher’s Exact test. Two-tailed Mann–
Whitney U test was used for comparisons of the SI levels
between two groups.
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